Time from completion of chemotherapy to disease progression as a clinically relevant endpoint in women with epithelial ovarian, primary peritoneal, and fallopian tube cancers treated with and without bevacizumab

✍ Scribed by Randall, L.; Burger, R.; Nguyen, H.; Kong, G.; Bookman, M.; Fleming, G.; Monk, B.; Mannel, R.; Birrer, M.

• Book ID: 122808613
• Publisher: Elsevier Science
• Year: 2013
• Tongue: English
• Weight: 181 KB
• Volume: 130
• Category: Article
• ISSN: 0090-8258
• DOI: 10.1016/j.ygyno.2013.04.346